Investor Presentaiton

69 Investor presentation Full year 2022 Novo NordiskⓇ In STEP 4, 41.2% of patients treated with semaglutide reached >20% weight loss and reported improved quality of life vs placebo Proportion of patients Categorical weight loss Sema 2.4 mg showed a statistically significant treatment difference versus placebo in the SF-36 patient reported outcome SF-36 scores 100% 90.5% Sema 2.4 mg Placebo Physical functioning 80.8% Role-physical 80% 65.5% 60% 50.0% 40% 20% H 20.9% 9.8% 41.2% Bodily pain General health Vitality Social functioning Role-emotional Mental health 5.1% Physical component summary Mental component summary 0% ≥5% ≥10% ≥15% ≥20% Weight loss Descriptive statistics only. Based on the on-treatment data, i.e. data for people that are on-treatment at week 68 Sema: semaglutide Favours placebo Favours semaglutide -1012 ETD [95% CI] 2.46 [1.593.32] 1.44 [0.42: 2.47] * * 2.23 [-0.06 4.53] 1.86 [0.733.00] * 4.31 [1.617.02] * 2.41 [0.07 4.76] * 1.64 [0.52: 2.76] * 2.93 [1.80 4.06] * 1.68 [0.64 2.72] * 3.44 [2.28 4.60] * 3 4 5 6 7 8 * statistically significant; p-values other than physical functioning were not controlled for multiplicity CI: confidence interval, ETD: estimated treatment difference, Sema: semaglutide, SF-36: Short Form (36) Health Survey

View entire presentation